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Kassem and Jamil1 describe 2 ap-
proaches for addressing systolic ante-
rior motion (SAM) after mitral valve
repair (MVRr). In the first approach
they describe an artificial chord from
a papillary muscle to the anterior an-
nulus on the ventricular side of the an-
terior leaflet. The chord serves to stop
the migration of excess anterior leaflet
into the outflow tract.
The second technique involves plac-
ing a diagonal artificial chord from the
posterior annulus (anchored into the an-
nuloplasty ring) around theA2 segment
of the anterior leaflet between the 5 and
7 o’clock positions. Again this presum-
ably restricts migration of the anterior
leaflet into the outflow tract.
My aim in addressing postrepair
SAM is to provide a relatively quick,
safe, and effective option without af-
fecting coaptation depth and hence
long-term repair durability. If signifi-
cant SAM persists after discontinua-
tion of cardiopulmonary bypass,
when possible the treatment should
be a relatively quick option to mini-
mize the duration of the additional
myocardial ischemic time.2
In theory the methods described
by Kassem and Jamil1 intuitively
make sense. However, I have a few
concerns:
1. Aside from personal experience,
the authors do not provide objec-
tive evidence that the measure-The Journalments they advocate for assessing
SAM risk are indeed risk factors
for SAM.
2. Placement of the papillary muscle
to the anterior annulus artificial
chord is often difficult and unlikely
to be routinely possible. Further-
more, the difficulty in placing this
suture may lead to inadvertent
crossing of the artificial chord over
normal native chordae, hence af-
fecting chord function. The authors
explain that in caseswhen this is not
possible, the diagonal artificial
chord option should be considered.
3. The diagonal chord is held in place
under the anterior leaflet and may
come in contact with native chor-
dae. I would be concerned for con-
stant friction between the artificial
chord and well-functioning native
primary and secondary chordae
and the possible risk for rupture
this presents over the long term. I
have observed chord rupture with
friction between 2 artificial chordae.
4. It is theoretically possible that an
excessively short diagonal chord
may lead to valve restriction during
diastole.
Clear evidence exists that a short
coaptation–septal distance and poste-
rior leaflet height greater than 15
mm indeed increases the risk for
SAM. Hence, my preference for effec-
tively shortening the posterior leaflet
with 1 artificial chord rather quickly
addresses both of these risk factors
without affecting coaptation depth. I
applaud the authors for their novel
techniques in addressing SAM and
providing additional options to the
surgeon.
Robin Varghese, MD, MS, FRCSC
Department of Cardiothoracic
Surgery
Mount Sinai Medical Center
New York, NY
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To the Editor:
We read with interest the article by
Li and colleagues1 recently published
in the Journal. They investigated the
distribution of lymph node metastasis
in thoracic esophageal squamous cell
carcinoma. This is an important topic
because several articles have shown
the relation between nodal involve-
ment and worse prognosis of these
patients.2,3
To achieve a homogeneous sample,
the authors included in the analysis
only patients who underwent R0 re-
section without neoadjuvant therapy,
which could modify nodal metastasis
pattern.4
The authors found paratracheal
lymph nodes as themost frequently in-
volved (15.9%), followed by middle
paraesophageal (14%), paracardial
(11.2%), and lower paraesophageal
(11%) lymph nodes.
In our previously published article,4
we found paraesophageal lymph no-
des as the most frequently involved
(31.9%) in a similar subsample (pa-
tients who underwent R0 resection
for thoracic esophageal squamous
cell carcinoma without neoadjuvant
therapy), followed by paracardial
(19.8%), perigastric (16.4%), and
subcarinal (11.2%) lymph nodes.
Despite small differences in percent-
ages (perhaps due to more superficial
esophageal cancer presented by Li
and colleagues), the results of both
articles1,4 suggest that a map of the
distribution of nodal metastasis might
provide useful information to plan
the operative technique and adequatery c Volume 145, Number 3 895
Letters to the Editorlymphadenectomy. According to the
literature, we think that different
maps based on histology (squamous
cell carcinoma or adenocarcinoma),
neoadjuvant therapy (performed or
not), and tumor site (upper thoracic,
middle thoracic, lower esophagus, or
esophagogastric junction) could be
made.
Moreover, we would like to under-
line the importance of the map of
nodal methastasis after neoadjuvant
therapy. In fact, the rate of esophageal
squamous cell carcinoma treated with
neoadjuvant therapy has increased
since the 1980s, and neoadjuvant
therapy followed by esophagectomy
currently is performed by most clini-
cians.5 A specific map for this therapy
pattern is worthwhile because the dis-
tribution of nodal metastasis could be
affected by preoperative treatment,4
and it requires a different map com-
pared with patients who undergo
only surgery.
This strategy could suggest the
most frequently involved lymph nodes
in each combination of the above-
mentioned variables, leading to an
improvement of the effectiveness of
surgery. Therefore, further studies
are needed to explore the reasonable-
ness of this idea, to exchange opinions
among research groups, and to gather
information for map construction.
Francesco Cavallin, MS
Marco Scarpa, MD, PhD
Carlo Castoro, MD
Oncological Surgery Unit
Veneto Institute of Oncology
(IOV-IRCCS)
Padova, ItalyReferences
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Although controversies still remain
in the management of esophageal can-
cer, and neoadjuvant therapy has not
been widely conducted in China, it is
obvious that neoadjuvant therapy
plays an important role. Over the
past decade, treatment strategy has
changed a lot in our center. Between
2000 and 2004, the McKeown proce-
dure with a 3-field lymphadenectomy
was performed unselectively to all
patients with esophageal cancer. Since
2005, Ivor-Lewis esophagectomy
with 2-field lymphadenectomy has
been widely performed, and the
3-field lymphadenectomy procedure
was selectively applied on the basis
of ultrasound and computed tomogra-
phy information considering a higher
risk of complications. Although adju-
vant chemoradiotherapy after surgery
was routinely performed for advanced
cancers, the prognosis remains disap-
pointing in our experience. Therefore,
we also think neoadjuvant therapy
could improve the prognosis of
surgery.
As mentioned in our article, only
30 of 1491 patients with squamous
cell carcinoma (SCC) received che-
motherapy or radiotherapy before
surgery between 2006 and 2010 in
our center.1 There are several factors.
Surgeon’s preference may be the first
issue. The idea of neoadjuvantardiovascular Surgery c March 2013therapy for esophageal cancer has
not been widely accepted by surgeons
in China. Different pathologic pat-
terns from the West and increased
risk of complications may be 2 im-
portant factors influencing their treat-
ment decision making. Because most
patients with esophageal cancer came
from poor rural areas, heavy treat-
ment costs and inadequate medical
insurance would be the second rea-
son. However, in 2011, China spent
only 4.98% of its gross domestic
product on health care. On the other
hand, patients traditionally prefer to
receive resection when the cancer is
pathologically confirmed, so patients’
compliance for neoadjuvant therapy
would be another major factor. Fi-
nally, lack of prospective trials was
the most important problem. One lat-
est study showed that preoperative
chemoradiotherapy could improve
survival among patients with poten-
tially curable esophageal cancer.2
However, the results were limited be-
cause of the small sample of patients
with SCC. More randomized trials
with a larger sample for neoadjuvant
therapy for those with SCC are still
needed.
At present, the treatment strategy
for esophageal cancer is not uniform
in China, not only the administration
of neoadjuvant therapy but also
the choice of surgical approach, re-
construction route, and extent of
lymphadenectomy. Considering the
frustrating prognosis, efforts are nec-
essary to improve the survival. Ran-
domized clinical trials are being
performed in our center. Because
the left thoracic procedure is widely
performed in China,3 one study com-
paring the left and right thoracic
approaches (ClinicalTrials.gov iden-
tifier, NCT01047111) has enrolled
300 patients with middle and lower
esophageal cancer since 2010, and
follow-up information is being col-
lected. Another study comparing
3-field lymphadenectomy and 2-field
lymphadenectomy is ready to begin
and has been approved by the
